Pneumologie 2023; 77(S 01): S7-S8
DOI: 10.1055/s-0043-1760883
DOI: 10.1055/s-0043-1760883
Abstracts
Durvalumab (D)+/− tremelimumab (T)+chemotherapy (CT) in 1L metastatic (m) NSCLC: overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)
Authors
-
F Griesinger
1 Pius-Hospital Oldenburg; University Medicine Oldenburg; Hematology/Oncology, Internal Medicine-Oncology -
M Johnson
2 Sarah Cannon Research Institute, Tennessee Oncology, Pllc -
B Cho
3 Yonsei Cancer Center -
A Luft
4 Leningrad Regional Clinical Hospital -
J Alatorre-Alexander
5 Health Pharma Professional Research -
S Geater
6 Prince of Songkla University -
K Laktionov
7 Federal State Budgetary Institution “n.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation (N.N. Blokhin Nmrco) -
S Kim
8 Asan Medical Center, University of Ulsan College of Medicine -
G Ursol
9 Acinus -
M Hussein
10 Florida Cancer Specialists – Sarah Cannon Research Institute -
F Lim
11 Queen Mary University of London -
C Yang
12 Chang Gung Memorial Hospital -
L Araujo
13 Instituto Nacional de Cancer-Inca -
H Saito
14 Kanagawa Cancer Center -
N Reinmuth
15 Asklepios Lungenklinik -
Z Lai
16 Astrazeneca -
H Mann
16 Astrazeneca -
X Shi
16 Astrazeneca -
S Peters
17 Centre Hospitalier Universitaire Vaudois, Lausanne University -
E Garon
18 David Geffen School of Medicine at Ucla -
T Mok
19 Chinese University of Hong Kong -
J Kern
20 Standort Missioklinik, Klinikum Würzburg Mitte gGmbH
